New drug IBI3031 enters first human trial for thyroid eye disease
NCT ID NCT07622368
First seen Jun 06, 2026 · Last updated Jun 21, 2026 · Updated 2 times
Summary
This early-stage trial tests the safety and tolerability of a new drug called IBI3031 in 66 people with moderate-to-severe active thyroid eye disease. Participants will receive either the drug or a placebo by injection or infusion. The study aims to find the right dose and check for side effects, but it is too early to know if the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3031
What this could lead to
If successful, this could point toward a new treatment option for thyroid eye disease, potentially reducing symptoms like bulging eyes and double vision.
What could go wrong
This is an early Phase 1 trial with only 66 participants, focused on safety. It may not show clear benefit, and side effects are unknown. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.